Who are ATG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antithymocyte globulin, Anti-Thymocyte Globulins treatment, rabbit anti-thymocyte globulin - 4 doses, tacrolimus, ATG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ATG — Competitive Intelligence Brief

ATG (ATG) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antithymocyte antibody. Area: Immunology.

marketed Polyclonal antithymocyte antibody T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ATG (ATG) — ITB-Med LLC. ATG (Antithymocyte Globulin) is a polyclonal antibody that depletes T lymphocytes by binding to T-cell antigens and triggering their destruction.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ATG TARGET	ATG	ITB-Med LLC	marketed	Polyclonal antithymocyte antibody	T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers)
Antithymocyte globulin	Antithymocyte globulin	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Polyclonal antithymocyte antibody	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
Anti-Thymocyte Globulins treatment	Anti-Thymocyte Globulins treatment	Nantes University Hospital	marketed	Polyclonal antithymocyte antibody	T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
rabbit anti-thymocyte globulin - 4 doses	rabbit anti-thymocyte globulin - 4 doses	University of Nebraska	marketed	Polyclonal antithymocyte antibody	T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
tacrolimus, ATG	tacrolimus, ATG	University Hospital, Toulouse	marketed	Calcineurin inhibitor and polyclonal antithymocyte antibody	Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antithymocyte antibody class)

ITB-Med LLC · 1 drug in this class
Nantes University Hospital · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
University of Nebraska · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/atg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab